<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32938991</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Changes in the concentrations of trimethylamine N-oxide (TMAO) and its precursors in patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>15198</StartPage><MedlinePgn>15198</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15198</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-72184-3</ELocationID><Abstract><AbstractText>To compare the plasma concentrations of trimethylamine N-oxide (TMAO) and its precursors in amyotrophic lateral sclerosis (ALS) patients, their spouses and healthy controls and to find associations between gut microbiota metabolites and ALS. ALS patients were recruited at Peking University Third Hospital from January 2015 to December 2018. Information was collected from their spouses at the same time. Age and gender matched healthy controls were recruited from individuals who visited the physical examination center for health checkups. Blood samples were collected after at least 4&#xa0;h of fasting. Concentrations of the metabolites were quantified using stable isotope dilution liquid chromatography-tandem mass spectrometry. Group differences were analyzed using parametric and nonparametric tests, as appropriate. In this study, 160 patients with ALS were recruited. In these patients, 63 were compared with their spouses, 148 were compared with age and gender matched controls, and 60 were compared with both their spouses and heathy controls in the same time. The carnitine concentration was significantly higher in patients than in their spouses, while there were no significant differences in the concentrations of other metabolites. The carnitine and betaine concentrations were higher, while the choline, TMAO and butyrobetaine concentrations were lower in ALS than in healthy controls. The concentrations of the metabolites in the spouses were more similar to the ALS patients rather than to the healthy controls. In the ALS group, the plasma concentrations of carnitine, betaine, choline and TMAO were inversely related to the severity of upper motor neuron impairment. The TMAO metabolic pathway of the gut microbiota is disturbed in both ALS patients and their spouses, which might suggest that the changes in the gut microbiota occurred before disease onset. The negative correlations between the involvement of UMNs and the concentrations of the metabolites might suggest that the inhibition of this metabolic pathway might lead to a better prognosis in ALS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Mingming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, Peking University Health Science Center, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education, Peking University Health Science Center, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zheng</LastName><ForeName>Lemin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, Peking University Health Science Center, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education, Peking University Health Science Center, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fan</LastName><ForeName>Dongsheng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, China. dsfan2010@aliyun.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Neuroscience, National Health Commission/Ministry of Education, Peking University, Beijing, China. dsfan2010@aliyun.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008744">Methylamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3SCV180C9W</RegistryNumber><NameOfSubstance UI="D001622">Betaine</NameOfSubstance></Chemical><Chemical><RegistryNumber>407-64-7</RegistryNumber><NameOfSubstance UI="C002889">gamma-butyrobetaine</NameOfSubstance></Chemical><Chemical><RegistryNumber>FLD0K1SJ1A</RegistryNumber><NameOfSubstance UI="C005855">trimethyloxamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N91BDP6H0X</RegistryNumber><NameOfSubstance UI="D002794">Choline</NameOfSubstance></Chemical><Chemical><RegistryNumber>S7UI8SM58A</RegistryNumber><NameOfSubstance UI="D002331">Carnitine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001622" MajorTopicYN="N">Betaine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002331" MajorTopicYN="N">Carnitine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002794" MajorTopicYN="N">Choline</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008744" MajorTopicYN="N">Methylamines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>17</Day><Hour>5</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32938991</ArticleId><ArticleId IdType="pmc">PMC7495434</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-72184-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-72184-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen L, et al. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J. Neurol. Neurosurg. Psychiatry. 2015;86:1075&#x2013;1081. doi: 10.1136/jnnp-2015-310471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310471</ArticleId><ArticleId IdType="pubmed">26124198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragonese P, et al. Incidence of amyotrophic lateral sclerosis in Sicily: a population based study. Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group Motor Neuron Dis. 2012;13:284&#x2013;287. doi: 10.3109/17482968.2012.662689.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.662689</ArticleId><ArticleId IdType="pubmed">22409362</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet (Lond., Engl.) 2011;377:942&#x2013;955. doi: 10.1016/s0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, et al. Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry. 2010;81:385&#x2013;390. doi: 10.1136/jnnp.2009.183525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>del Aguila MA, Longstreth WT, Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003;60:813&#x2013;819. doi: 10.1212/01.wnl.0000049472.47709.3b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000049472.47709.3b</ArticleId><ArticleId IdType="pubmed">12629239</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, et al. The epidemiology of ALS and the role of population-based registries. Biochim. Biophys. Acta. 2006;1762:1150&#x2013;1157. doi: 10.1016/j.bbadis.2006.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.09.008</ArticleId><ArticleId IdType="pubmed">17071060</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al. Prognostic factors in ALS: a critical review. Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group Motor Neuron Dis. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013;14:248&#x2013;264. doi: 10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Faglioni P, Nichelli P, Sola P. Amyotrophic lateral sclerosis: prognostic indicators of survival. Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group Motor Neuron Dis. 2006;7:211&#x2013;220. doi: 10.1080/17482960600947648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600947648</ArticleId><ArticleId IdType="pubmed">17127559</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M, et al. Natural history of young-adult amyotrophic lateral sclerosis. Neurology. 2008;71:876&#x2013;881. doi: 10.1212/01.wnl.0000312378.94737.45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000312378.94737.45</ArticleId><ArticleId IdType="pubmed">18596241</ArticleId></ArticleIdList></Reference><Reference><Citation>Govoni V, Granieri E, Fallica E, Casetta I. Amyotrophic lateral sclerosis, rural environment and agricultural work in the Local Health District of Ferrara, Italy, in the years 1964&#x2013;1998. J. Neurol. 2005;252:1322&#x2013;1327. doi: 10.1007/s00415-005-0859-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-005-0859-z</ArticleId><ArticleId IdType="pubmed">15995797</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui F, et al. Epidemiological characteristics of motor neuron disease in Chinese patients. Acta Neurol. Scand. 2014;130:111&#x2013;117. doi: 10.1111/ane.12240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12240</ArticleId><ArticleId IdType="pubmed">24689740</ArticleId></ArticleIdList></Reference><Reference><Citation>Zufiria M, et al. ALS: a bucket of genes, environment, metabolism and unknown ingredients. Prog. Neurobiol. 2016;142:104&#x2013;129. doi: 10.1016/j.pneurobio.2016.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2016.05.004</ArticleId><ArticleId IdType="pubmed">27236050</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R, Wang Q. Towards understanding brain-gut-microbiome connections in Alzheimer&#x2019;s disease. BMC Syst. Biol. 2016;10(Suppl 3):63. doi: 10.1186/s12918-016-0307-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12918-016-0307-y</ArticleId><ArticleId IdType="pmc">PMC5009560</ArticleId><ArticleId IdType="pubmed">27585440</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson TR, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson&#x2019;s disease. Cell. 2016;167:1469&#x2013;1480.e1412. doi: 10.1016/j.cell.2016.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.11.018</ArticleId><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="pubmed">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X. Potential role of gut microbiota and tissue barriers in Parkinson&#x2019;s disease and amyotrophic lateral sclerosis. Int. J. Neurosci. 2016;126:771&#x2013;776. doi: 10.3109/00207454.2015.1096271.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00207454.2015.1096271</ArticleId><ArticleId IdType="pubmed">26381230</ArticleId></ArticleIdList></Reference><Reference><Citation>Longstreth WT, Jr, et al. Hypothesis: a motor neuron toxin produced by a clostridial species residing in gut causes ALS. Med. Hypotheses. 2005;64:1153&#x2013;1156. doi: 10.1016/j.mehy.2004.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2004.07.041</ArticleId><ArticleId IdType="pubmed">15823706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Yi J, Zhang YG, Zhou J, Sun J. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol. Rep. 2015 doi: 10.14814/phy2.12356.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.12356</ArticleId><ArticleId IdType="pmc">PMC4425962</ArticleId><ArticleId IdType="pubmed">25847918</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572:474&#x2013;480. doi: 10.1038/s41586-019-1443-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1443-5</ArticleId><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57&#x2013;63. doi: 10.1038/nature09922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09922</ArticleId><ArticleId IdType="pmc">PMC3086762</ArticleId><ArticleId IdType="pubmed">21475195</ArticleId></ArticleIdList></Reference><Reference><Citation>Koeth RA, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013;19:576&#x2013;585. doi: 10.1038/nm.3145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3145</ArticleId><ArticleId IdType="pmc">PMC3650111</ArticleId><ArticleId IdType="pubmed">23563705</ArticleId></ArticleIdList></Reference><Reference><Citation>Kira Y, Nishikawa M, Ochi A, Sato E, Inoue M. L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis. Brain Res. 2006;1070:206&#x2013;214. doi: 10.1016/j.brainres.2005.11.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2005.11.052</ArticleId><ArticleId IdType="pubmed">16412993</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 2013;14:397&#x2013;405. doi: 10.3109/21678421.2013.764568.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.764568</ArticleId><ArticleId IdType="pubmed">23421600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett BJ, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013;17:49&#x2013;60. doi: 10.1016/j.cmet.2012.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2012.12.011</ArticleId><ArticleId IdType="pmc">PMC3771112</ArticleId><ArticleId IdType="pubmed">23312283</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazalpour A, Cespedes I, Bennett BJ, Allayee H. Expanding role of gut microbiota in lipid metabolism. Curr. Opin. Lipidol. 2016;27:141&#x2013;147. doi: 10.1097/mol.0000000000000278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/mol.0000000000000278</ArticleId><ArticleId IdType="pmc">PMC5125441</ArticleId><ArticleId IdType="pubmed">26855231</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, El Munsat TL. Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. Off. Publ. World Fed. Neurol. Res. Group Motor Neuron Dis. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T, Heaney LM, Jones DJ, Ng LL. Trimethylamine N-oxide and risk stratification after acute myocardial infarction. Clin. Chem. 2017;63:420&#x2013;428. doi: 10.1373/clinchem.2016.264853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2016.264853</ArticleId><ArticleId IdType="pubmed">28062632</ArticleId></ArticleIdList></Reference><Reference><Citation>Guertin KA, et al. Serum trimethylamine N-oxide, carnitine, choline, and betaine in relation to colorectal cancer risk in the alpha tocopherol, beta carotene cancer prevention study. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 2017;26:945&#x2013;952. doi: 10.1158/1055-9965.Epi-16-0948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.Epi-16-0948</ArticleId><ArticleId IdType="pmc">PMC5608021</ArticleId><ArticleId IdType="pubmed">28077427</ArticleId></ArticleIdList></Reference><Reference><Citation>Senthong V, et al. Plasma trimethylamine N-oxide, a gut microbe-generated phosphatidylcholine metabolite, is associated with atherosclerotic burden. J. Am. Coll. Cardiol. 2016;67:2620&#x2013;2628. doi: 10.1016/j.jacc.2016.03.546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.03.546</ArticleId><ArticleId IdType="pmc">PMC4893167</ArticleId><ArticleId IdType="pubmed">27256833</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Q, et al. Coronary plaque characterization assessed by optical coherence tomography and plasma trimethylamine-N-oxide levels in patients with coronary artery disease. Am. J. Cardiol. 2016;118:1311&#x2013;1315. doi: 10.1016/j.amjcard.2016.07.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2016.07.071</ArticleId><ArticleId IdType="pubmed">27600460</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson A, et al. Trimethylamine-N-oxide: a novel biomarker for the identification of inflammatory bowel disease. Dig. Dis. Sci. 2015;60:3620&#x2013;3630. doi: 10.1007/s10620-015-3797-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-015-3797-3</ArticleId><ArticleId IdType="pubmed">26160437</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang WH, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 2015;116:448&#x2013;455. doi: 10.1161/circresaha.116.305360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.116.305360</ArticleId><ArticleId IdType="pmc">PMC4312512</ArticleId><ArticleId IdType="pubmed">25599331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasheras I, et al. Microbiota and gut-brain axis dysfunction in autism spectrum disorder: evidence for functional gastrointestinal disorders. Asian J. Psychiatry. 2019;47:101874. doi: 10.1016/j.ajp.2019.101874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajp.2019.101874</ArticleId><ArticleId IdType="pubmed">31785441</ArticleId></ArticleIdList></Reference><Reference><Citation>Fattorusso A, Di Genova L, Dell'Isola GB, Mencaroni E, Esposito S. Autism spectrum disorders and the gut microbiota. Nutrients. 2019 doi: 10.3390/nu11030521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11030521</ArticleId><ArticleId IdType="pmc">PMC6471505</ArticleId><ArticleId IdType="pubmed">30823414</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheperjans F, et al. Gut microbiota are related to Parkinson&#x2019;s disease and clinical phenotype. Mov. Disord. Off. J. Mov. Disord. Soc. 2015;30:350&#x2013;358. doi: 10.1002/mds.26069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26069</ArticleId><ArticleId IdType="pubmed">25476529</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, et al. Gut microbiota in ALS: possible role in pathogenesis? Expert Rev. Neurother. 2019;19:785&#x2013;805. doi: 10.1080/14737175.2019.1623026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2019.1623026</ArticleId><ArticleId IdType="pubmed">31122082</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Houser M, Tansey MG, Glass JD, Hertzberg VS. The gut microbiome and neuroinflammation in amyotrophic lateral sclerosis? Emerging clinical evidence. Neurobiol. Dis. 2018 doi: 10.1016/j.nbd.2018.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.10.007</ArticleId><ArticleId IdType="pubmed">30321601</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, et al. Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. Eur. J. Neurol. 2019;26:1355&#x2013;1361. doi: 10.1111/ene.13986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13986</ArticleId><ArticleId IdType="pubmed">31087715</ArticleId></ArticleIdList></Reference><Reference><Citation>Pekala J, et al. L-carnitine-metabolic functions and meaning in humans life. Curr. Drug Metab. 2011;12:667&#x2013;678. doi: 10.2174/138920011796504536.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920011796504536</ArticleId><ArticleId IdType="pubmed">21561431</ArticleId></ArticleIdList></Reference><Reference><Citation>Manta-Vogli PD, Schulpis KH, Dotsikas Y, Loukas YL. The significant role of carnitine and fatty acids during pregnancy, lactation and perinatal period. Nutritional support in specific groups of pregnant women. Clin. Nutr. (Edinb. Scotl.) 2019 doi: 10.1016/j.clnu.2019.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2019.10.025</ArticleId><ArticleId IdType="pubmed">31732292</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaguarnera M, Cauli O. Effects of l-carnitine in patients with autism spectrum disorders: review of clinical studies. Molecules (Basel Switz.) 2019 doi: 10.3390/molecules24234262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24234262</ArticleId><ArticleId IdType="pmc">PMC6930613</ArticleId><ArticleId IdType="pubmed">31766743</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A, Coccurello R. What is &#x201c;hyper&#x201d; in the ALS hypermetabolism? Mediators Inflamm. 2017;2017:7821672. doi: 10.1155/2017/7821672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7821672</ArticleId><ArticleId IdType="pmc">PMC5610793</ArticleId><ArticleId IdType="pubmed">29081604</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J. Neurol. Neurosurg. Psychiatry. 2018;89:1016&#x2013;1023. doi: 10.1136/jnnp-2017-317887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S. Hypermetabolism appears to be an adverse prognostic biomarker in amyotrophic lateral sclerosis: a potential for therapeutic intervention? Eur. J. Neurol. 2018;25:1&#x2013;2. doi: 10.1111/ene.13470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13470</ArticleId><ArticleId IdType="pubmed">28940741</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, et al. Prognostic factors in ALS: a comparison between Germany and China. J. Neurol. 2019;266:1516&#x2013;1525. doi: 10.1007/s00415-019-09290-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09290-4</ArticleId><ArticleId IdType="pubmed">30923935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M, et al. Uncovering amyotrophic lateral sclerosis phenotypes: clinical features and long-term follow-up of upper motor neuron-dominant ALS. Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group Motor Neuron Dis. 2011;12:278&#x2013;282. doi: 10.3109/17482968.2011.580849.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.580849</ArticleId><ArticleId IdType="pubmed">21702734</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, et al. C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature. 2020;582:89&#x2013;94. doi: 10.1038/s41586-020-2288-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2288-7</ArticleId><ArticleId IdType="pmc">PMC7416879</ArticleId><ArticleId IdType="pubmed">32483373</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>